Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on June 25, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Investigating Associations Between Acute Abuse Liability Outcomes and Switching Behavior

Closed
75F40126R00031Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The contract seeks a contractor to investigate associations between acute abuse liability outcomes and switching behavior, focusing on clinical studies involving experienced combusted cigarette users and Electronic Nicotine Delivery Systems (ENDS). The work encompasses recruiting participants, selecting and obtaining tobacco products based on market popularity and FDA authorization, administering products in controlled laboratory and ambulatory settings, and collecting behavioral, pharmacological, and biological data. The contractor must conduct statistical analyses of nicotine pharmacokinetics and user behaviors, produce a draft and final clinical study protocol with peer review, secure OMB and IRB clearances, and deliver a final study report within two months of receiving FDA feedback, with a possible revised report if additional comments arise. Performance is to occur at the contractor’s facility over a four-year period under a firm-fixed-price contract, with deliverables including biweekly meetings, monthly progress reports due by the 10th of each month, kick-off and NPI form submissions within 10 and 30 business days of award, and weekly recruitment updates once recruitment begins. The government will not provide any property or materials, and no travel or unique security requirements exist. The solicitation requires active SAM registration with a valid UEI, compliance with FAR and HHSAR clauses including safeguarding information systems, whistleblower protections, equal opportunity, contractor ethics, and combating trafficking in persons, with the deviation clause 52.212-4 applying. Offerors must submit a technical proposal not exceeding 15 pages with a project timeline and a separately formatted price proposal listing labor categories, hours, pricing discounts, and a completed pricing table. Past performance must include up to three comparable federal, foundation, or private contracts completed within the past five years, with points of contact provided. Proposals must be emailed to Janice Heard by July 6, 2026, at 2:00 p.m. ET, in Microsoft Office format without macros or executable files. Evaluation favors technical understanding and approach as the most important factor, followed by past performance, staffing plan, key personnel qualifications, and price, with best value as the basis for award and non-price factors significantly more important than price. Payment is electronic via the Treasury’s IPP system, contingent on government acceptance and certification of deliverables, with payment withheld for nonconforming work or stoppages beyond FDA control, and must include an invoice log addendum tracking all prior payments and remaining estimated amounts. The contract is not set aside for small businesses.

General Info

FDA contract to study links between abuse liability outcomes and switching behavior in Maryland.

Agency

Department Of Health And Human Services → FDA Office Of Acq Grant SvcsView Agency

NAICS

541380 - Testing Laboratories and ServicesView NAICS

Place of Performance

Silver Spring, MD, 20993, USA

Set-Aside

NONE

Documents

(2)

Solicitation 75F40126R00031 Investigating Acute Abuse Liability Outcomes

PDFrfp

Q&A for RFP 75F40126R00031

DOCXq-and-a

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

1 update
PhaseClosed
Posted

Combined Synopsis

Amendment 1

Contract was updated

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → FDA Office Of Acq Grant Svcs
Contacts1 person available
OfficeRockville, MD, 20852, USA
Organization / Agency
Department Of Health And Human Services → FDA Office Of Acq Grant Svcs
View Agency Profile
Office AddressRockville, MD, 20852, USA

Full Description

Show more

Request for Investigating associations between acute abuse liability outcomes and switching behavior.  See attached soliciation for full details.

More opportunities from Department Of Health And Human Services → FDA Office Of Acq Grant Svcs

Same awarding agency

NAICS: 541714
New
Federal
Human Hindbrain Organoid Functional Assay Services.
Solicitation # RFQ_CDR-2026-135968
The U.S. Food and Drug Administration, through the Center for Drug Evaluation and Research, intends to award a sole-source, firm-fixed-price purchase order to OrganoTherapeutics SARL for human iPSC-derived hindbrain organoid functional assay services. This acquisition, conducted under FAR Part 12 as a commercial service, aims to support in vitro research on drug-induced effects on respiratory-relevant neural circuits. The scope of work includes the provision of human hindbrain organoids and associated culture materials, with twelve scheduled deliveries to the FDA White Oak Campus in Silver Spring, Maryland. The first delivery will consist of 96 organoids, followed by eleven subsequent deliveries of 48 organoids each. The contractor will perform functional characterization at its own laboratory using three-dimensional multi-electrode array technology to assess electrophysiological responses to FDA-identified drug and reversal-agent combinations. Key deliverables include the raw and analyzed data, analysis files, and comprehensive study reports. The anticipated period of performance is 18 months from the date of award. Award will be based on best value, with technical capability and past performance weighted more heavily than price. All invoicing must be processed electronically through the U.S. Department of Treasury's Invoice Processing Platform.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 21 hours ago

DEADLINE

in 5 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS